WallStreetZenWallStreetZen

NASDAQ: IPHA
Innate Pharma Sa Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

IPHA past revenue growth

How has IPHA's revenue growth performed historically?
Company
11.63%
Industry
144.63%
Market
17.55%
IPHA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IPHA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IPHA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IPHA earnings and revenue history

Current Revenue
$68.5M
Current Earnings
-$8.4M
Current Profit Margin
-12.3%

IPHA Return on Equity

Current Company
-14.3%
Current Industry
-63.5%
Current Market
188%
IPHA's Return on Equity (-14.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when IPHA announces earnings.

IPHA Return on Assets

Current Company
-3.9%
Current Industry
2.9%
IPHA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IPHA Return on Capital Employed

Current Company
-3.97%
Current Industry
19.5%
IPHA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IPHA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IPHA$67.00M-$700.00k-$8.23M-8.70%N/A
ANVS$0.00-$56.20M-$56.20MN/AN/A
OPT$385.28k-$134.99M-$142.52M-14.20%N/A
CMPX$0.00-$40.60M-$42.49MN/AN/A
ZVRA$27.46M-$43.54M-$46.05M+20.93%N/A
View Top Biotech Stocks

IPHA earnings dates

Next earnings date
May 14, 2024

Innate Pharma Sa Earnings & Revenue FAQ

What were IPHA's earnings last quarter?

On Invalid Date, Innate Pharma Sa (NASDAQ: IPHA) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Innate Pharma Sa earnings for the quarter were N/A. In the same quarter last year, Innate Pharma Sa's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Innate Pharma Sa stock.

What was IPHA's earnings growth in the past year?

As of Q2 2024, Innate Pharma Sa's earnings has grown year over year. Innate Pharma Sa's earnings in the past year totalled -$8.23 million.

What is IPHA's earnings date?

Innate Pharma Sa's earnings date is Invalid Date. Add IPHA to your watchlist to be reminded of IPHA's next earnings announcement.

What was IPHA's revenue last quarter?

On Invalid Date, Innate Pharma Sa (NASDAQ: IPHA) reported Q4 2023 revenue of N/A up N/A year over year. In the same quarter last year, Innate Pharma Sa's revenue was N/A.

What was IPHA's revenue growth in the past year?

As of Q2 2024, Innate Pharma Sa's revenue has grown 11.63% year over year. This is 133 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Innate Pharma Sa's revenue in the past year totalled $67.00 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.